BiomX (NYSEAMERICAN:PHGE) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of BiomX (NYSEAMERICAN:PHGE) in a report issued on Monday,Benzinga reports.

BiomX Trading Up 9.0%

PHGE stock opened at $7.42 on Monday. BiomX has a 1-year low of $1.50 and a 1-year high of $14.71. The firm has a market cap of $11.80 million, a PE ratio of -0.29 and a beta of 1.68. The business’s 50-day moving average price is $4.37 and its two-hundred day moving average price is $6.54.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. On average, analysts forecast that BiomX will post -2.77 earnings per share for the current year.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new position in BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX at the end of the most recent quarter. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.